PT. Yarindo Farmatama merupakan perusahaan yang baru merintis bidang usaha dalam kategori obat hewan. Sebelumnya perusahaan ini bergerak dalam bidang obat manusia dan merupakan salah satu anak perusahaan dari perusahaan besar farmasi yang namanya sudah tidak asing lagi, Fahrenheit.

Meski tergolong “baru” dalam industri obat hewan, perusahaan ini menujukkan cikal bakal yang kuat hingga dapat bersaing dengan industri obat hewan yang sudah ada sebelumnya. Ini dapat dilihat dari sejarah perusahaan ini berdiri, visi, misi serta goals yang dimiliki oleh perusahaan ini.


  • Vision: To become a leading pharmaceutical company in Indonesia that focus on specialty pharmaceutical products.


  • Mission: We consistently provide improvements in product quality and cost reduction through continuous innovation and collaboration to serve customers with products of the highest quality in order to gain their respect and loyalty.


  • Responsibility: To create products that fulfill safety, efficacy, and quality requirements in accordance with the guidelines set by the international health authorities.


  • Company values

    • H-uman resources that are capable and dedicated
    • E- ffecctive and efficient
    • A-n amicable and harmonious work environment
    • L- earning through experience for the betterment of the company
    • T-horough and detailed
    • H-igh quality



Fahrenheit’s first manufacturing facility was constructed in a major industrial complex in Tangerang, West Java on two hectares of land. Its first commercial batch consisted of cardiovascular drugs and vitamins prepared in simple oral forms. Since then, the plant’s technology and facilities have been continuously upgraded several times to offer only the highest quality products.

  • In 1994, Fahrenheit expanded its manufacturing and added oral and injectable Cephalosporine to its lineup.
  • Another expansion was completed in 1995 to accommodate the manufacturing of small-volume parenteral (SVP) and ophthalmic products.
  • Despite the economic crisis of 1998 in Asia, the company aggressively expanded its manufacturing capabilities to develop large volume parenteral products with a focus on antibiotics.
  • Our investment in oral and injectable hormone contraceptive products bore fruit in 2004.
  • A new facility was constructed to accommodate the increased demand for oral and injectable Cephalosporine in 2010.
  • By 2012, the company invested in a larger SVP plant complete with a lyophilized facility.
  • We finished construction of a larger facility for LVP products in 2015 and we are currently building an additional plant for our oral dosage preparations due to be finished in 2017.
  • All of Fahrenheit’s practices comply with the GMP International Standards to develop an assortment of ethical products for:
    • cardiovascular,
    • hematopoietic,
    • respiratory,
    • metabolic,
    • alimentary,
    • genitourinary systems,
    • antibiotics and vitamins from simple oral forms two injectable forms including IV solutions.

With the company’s wide range of capabilities, it has positioned itself as a major branded generic manufacturing company in Indonesia focusing on specialty products.


Other groups of companies: PT. Yarindo Farmatama and PT. Dian Langgeng Pratama

The financial crisis of 1998 in Indonesia saw a shift in market growth from branded generic market to the lower generic market. Seeing this as an opportunity, Fahrenheit decided to enter the market by establishing its subsidiary generic manufacturing company, PT. Yarindo Farmatama, located in Serang, Banten.

In over five years since its inception, PT. Yarindo Farmatama has enjoyed a growth rate of more than 50% annually. Both companies have given an unsurpassed competitive advantage as they have been able to penetrate aggressively in the ethical market. As a result of such strong growth in the medical segment, Fahrenheit decided to establish another subsidiary company, PT. Dian Langgeng Pratama to promote medical equipment.

At this moment, PT. Dian Langgeng Pratama is responsible for marketing and distributing imported medical products. We are able to closely monitor the logistics of these products which require special care and treatment. However, we won’t stop there as Fahrenheit is still seeking reliable partners to market and distribute its niche medical products. In the near future, PT. Dian Langgeng Pratama is planning to invest in manufacturing facilities for these medical devices. Our expansions and development show Fahrenheit’s deep commitment in the medical market and we are proud to say that more plans for expansion are being constructed to fulfill our passion for growth.




Similar Posts:

Status Perusahaan
Swasta Nasional
Rating & Reviews
0 reviews
Contact Form

Sign up for Newsletter

Sign up to get our latest exclusive updates, deals, offers and promotions.